FARMINGTON, Conn., June 18, 2012 /PRNewswire-iReach/ -- While the drug discovery markets have proven resilient against recession, as the worldwide economy recovers into a new period of growth there is little doubt these developments will have a positive effect on the market, and having accurate market data and analysis will be essential to companies seeking to compete against the shifting landscape. With premium market research from the world's leading publishers, Global Information, Inc. helps businesses stay on the cutting edge with the best forecasts, research, and analyses.
Global Information is pleased to announce the immediate availability of two significant new reports on the global drug discovery markets:
Drug Discovery Technologies
The billion-dollar drug discovery industry is highly dependent on tools such as High-Throughput Screening, Bioanalytical instrument, Cell-based assays, Proteomics, Genomics, and Bioinformatics. As the global market for drug discovery technologies and products expands to $41.4 billion in 2012 and to $79.0 billion in 2017 (a CAGR of 13.8% between 2012 and 2017), the high-throughput screening market will grow along side it, from $11.5 billion in 2012 to $20.0 billion in 2017 (11.7% CAGR), as will the bioanalytical instruments market, from $10.0 billion in 2012 to $15.0 billion in 2017 (8.4% CAGR).
Drug development lead time has not followed the rapid development of these tools, showing a gap between the initial introduction of new platforms and their further application and commercial success. Because of the complexity of biological and pathological conditions, it is critical to understand the effect of a technology or platform in drug discovery application, with each category requiring individual approaches. BCC research's new "Drug Discovery Technologies" market research report discusses the business strategies of each type of market participant (technology developers, manufacturer/ suppliers, and biotech companies) with positive or negative drivers and market trends.
For more details, including an executive summary and free sample pages, visit the reports information page at http://www.giiresearch.com/report/bc244530-drug-discovery-technologies.html
Re-evaluating Pharmaceutical Pipelines - Emerging Markets, Biologics and Orphan Drugs to Shape Future Decision Making
The closed systems of innovation within the pharmaceuticals industry heavily leverage in-house expertise, but create isolated paths of discovery, further slowing the already lengthy process of bringing new drugs to market. According to new market research by pharmaceutical experts at GBI Research, cooperation will be key to the successful development of pharmaceuticals in the coming years.
Over the next ten years, the pharmaceutical industry will seek new ways to improve and accelerate the drug development process. GBI Research's new report. "Re-evaluating Pharmaceutical Pipelines - Emerging Markets, Biologics and Orphan Drugs to Shape Future Decision Making", provides an overview of different strategies available to companies to acquire, partner or license products. It addresses key issues influencing the re-evaluation of pharmaceutical pipelines, and reviews the strategies the industry has adopted.
The report will help Pharmaceutical companies to develop business strategies to optimize strategic acquisitions, collaborations and partnerships and licensing deals, thus preventing late stage product failures.
An Executive Summary of this analysis and a free sample of the full report are available at http://www.giiresearch.com/report/gbi244539-re-evaluating-pharmaceutical-pipelines-emerging.html
10th annual Discovery on Target Conference
October 1 - 3, 2012 | Boston, MA
Discovery on Target offers attendees the opportunity to explore current "hot" targets, including GPCRs, Kinases and Histone Deacetylases, as well as to discover the "new kids on the block" which show a very promising future, such as Ubiquitin, Histone Methyl Transferases and PI3K. In addition, new developments and strategies to target some of the most prevalent diseases are being presented in focused meetings such as Cancer Cell Metabolism, Diabetes Drug Discovery, Allosteric Modulators and Functional Genomic Screening Strategies.
Save $380 by registering before July 13! Additional information and Early Bird discounted rates are available at http://www.giiconference.com/chi229591-2012/
About Global Information, Inc. Global Information (GII) (http://www.giiresearch.com) is an information service company partnering with over 300 research companies around the world. Global Information has been in the business of distributing technical and market research for more than 25 years. Expanded from its original headquarters in Japan, Global Information now has offices in Korea, Taiwan, Singapore, Europe and the United States.Media Contact:
Jeremy Palaia Global Information, Inc., 1-860-674-8796, Press@gii.co.jp
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
|SOURCE Global Information, Inc.|
Copyright©2012 PR Newswire.
All rights reserved